1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
REIFSNIDER O, PIMPLE P, STARGARDTER M, BRAND S, DESAI N, SHETTY S. 1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. Diabetes 2020, 69 DOI: 10.2337/db20-1158-p.Peer-Reviewed Original ResearchBoehringer Ingelheim PharmaceuticalsUse of empagliflozinT2D patientsCardiovascular diseaseAdverse eventsUnited Kingdom Prospective Diabetes Study (UKPDS) risk equationsGLP-1 receptor agonistsT2D-related complicationsSecond-line therapyType 2 diabetesClinical trial resultsTreatment-induced changesBackground metforminCVD subgroupsCV deathRenal outcomesHazard ratioClinical outcomesSGLT2 inhibitorsCVS CaremarkMyocardial infarctionReceptor agonistSpouse/partnerImproved outcomesDrug classes1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
SHARMA A, OFSTAD A, AHMAD T, ZINMAN B, ZWIENER I, FITCHETT D, WANNER C, GEORGE J, HANTEL S, DESAI N, MENTZ R. 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1144-p.Peer-Reviewed Original ResearchCV deathNovartis Pharmaceuticals CorporationPhenotype of patientsTreatment effectsEli LillyEMPA-REG OUTCOMERisk of outcomesType 2 diabetesAdvisory PanelBoehringer Ingelheim PharmaceuticalsBristol-Myers SquibbEMPA-REGMundipharma InternationalSanofi GenzymeCardiovascular deathCV diseaseT2D durationOlder patientsYounger patientsHeart failureAtherosclerotic diseaseSGLT2 inhibitionCox regressionDohme Corp.Patients